Stereotaxis Reports 13% Revenue Decline in Q2 2026, Acquires Robocath for $20 Million

Stereotaxis, Inc. reported a decline in financial performance for the second quarter of 2026, with total revenue decreasing by 13% to $7.7 million compared to $8.8 million in the same period last year. The company's revenue from system sales fell sharply from $3.0 million to $1.5 million, attributed to reduced sales volume. However, revenue from disposables, services, and accessories increased by approximately 7% to $6.2 million, driven by higher sales of Stereotaxis-supplied catheters, including the proprietary MAGiC ablation catheter. For the first half of 2026, total revenue was $14.0 million, down from $16.3 million in the prior year.

The company's cost of revenue also decreased, dropping from $4.2 million in Q2 2025 to $3.2 million in Q2 2026, resulting in an overall gross margin increase to 58% from 52%. This improvement was primarily due to a favorable product mix. Operating expenses rose slightly, with research and development costs increasing by 34% to $2.4 million, while sales and marketing expenses decreased by 21% to $2.6 million. General and administrative expenses saw a modest increase of 2% to $4.1 million. The net loss attributable to common stockholders for the second quarter was $4.8 million, compared to a loss of $4.1 million in the same quarter of 2025.

Stereotaxis has made significant strategic moves, including the completion of its acquisition of Robocath on July 7, 2026, for approximately $20 million in cash and stock. This acquisition is expected to enhance the company's capabilities in interventional cardiology and neurointerventions. The company has also received regulatory clearances for several products, including the GenesisX RMN System and the MAGiC catheter, which are anticipated to drive future growth.

Operationally, Stereotaxis reported an increase in its customer base, with hundreds of electrophysiologists at over 100 hospitals globally having treated more than 150,000 arrhythmia patients using its robotic technology. The company continues to face challenges related to supply chain disruptions and inflationary pressures, which could impact its ability to meet customer demand and maintain profitability. As of June 30, 2026, Stereotaxis had $10.5 million in cash and cash equivalents, with a working capital of $11.2 million.

Looking ahead, Stereotaxis plans to continue advancing the adoption of its robotic magnetic navigation systems and proprietary devices, while also managing the integration of Robocath. The company expects to incur additional losses in 2026 as it invests in research and development, sales, and marketing initiatives. Despite the challenges, Stereotaxis remains focused on expanding its market presence and achieving regulatory approvals for its innovative products.